J&J Directors Find Root Causes But Little Blame For OTC Quality Issues
This article was originally published in The Tan Sheet
A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.
You may also be interested in...
Plan B One-Step gets generic competition; legislation to restrict DXM introduced again; J&J agrees to reforms in settlement; China recants on MJN formula concerns; Buster line drives Hi-Tech Pharmacal OTC growth; Sabinsa awarded profits from infringed ForsLean trademark; more news In Brief.
Readers of “The Tan Sheet” in 2011 showed the most interest in stories about Johnson & Johnson’s OTC quality issues, Pfizer’s consumer business maneuvers and Rx-to-OTC switch outlooks. Other hot topics included omega-3 drug development, supplement GMP strategies and state pseudoephedrine laws.
Shareholder suit against Johnson & Johnson, including CFO Caruso, may proceed; Novartis pauses OTC production at Nebraska plant; Mead Johnson finds Enfamil powder clear of bacteria after stores pull the product; John Gay leaves NPA after two years as executive director and CEO; more news In Brief.